Asclepix Therapeutics, LLC

Lutherville, MD 21093

SBIR Award Summary

Total Number of Awards 6
Total Value of Awards $1.96MM
First Award Date 07/01/14
Most Recent Award Date 09/30/17

Key Personnel

Last Name Name Awards Contact
PANDEY NIRANJAN PANDEY 6

6 Awards Won

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PAR-14-088
Budget: 09/30/17 - 08/31/18

Summary Macular edema (ME) and diabetic macular edema (DME), which affects at least 2 million people in the US, are leading causes of blindness in people between the ages of 20-74. The major problem in these diseases is a leaky vasculature, which results in pooling of blood around the retina. This blood can cause occlusion of vision as well ...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-14-071
Budget: 09/01/15 - 08/31/16

DESCRIPTION (provided by applicant): Macular edema (ME) is a common disease secondary to retinal vein occlusion and both Type I and Type 2 Diabetes. It is the leading cause of blindness in people between the ages of 20-74. Lucentis and Eylea have been approved for the treatment of ME. Although effective, they do not increase the visual acuity fo...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-13-234
Budget: 07/01/15 - 09/30/15

DESCRIPTION (provided by applicant): Long-term anti-angiogenic activity of intravitreal ellipsoid particles for NVAMD Niranjan B. Pandey, Ph.D. - PI Aleksander S. Popel, Ph.D. - Co-I Jordan J. Green Ph.D. - Co-I Peter A. Campochiaro M.D. - Co-I of subaward Project Summary: Current therapies for wet age-related macular degeneration (AMD) targe...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-13-234
Budget: 07/01/14 - 06/30/15

DESCRIPTION (provided by applicant): Long-term anti-angiogenic activity of intravitreal ellipsoid particles for NVAMD Niranjan B. Pandey, Ph.D. - PI Aleksander S. Popel, Ph.D. - Co-I Jordan J. Green Ph.D. - Co-I Peter A. Campochiaro M.D. - Co-I of subaward Project Summary: Current therapies for wet age-related macular degeneration (AMD) targe...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-13-234
Budget: 07/01/14 - 06/30/15

DESCRIPTION (provided by applicant): Long-term anti-angiogenic activity of intravitreal ellipsoid particles for NVAMD Niranjan B. Pandey, Ph.D. - PI Aleksander S. Popel, Ph.D. - Co-I Jordan J. Green Ph.D. - Co-I Peter A. Campochiaro M.D. - Co-I of subaward Project Summary: Current therapies for wet age-related macular degeneration (AMD) targe...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PAR-10-286
Budget: 07/01/14 - 03/31/15

DESCRIPTION (provided by applicant): There are very limited options currently available for the treatment of HPV(-) head and neck squamous cell cancer (HNSCC), the sixth leading cause of cancer in the United States and worldwide. HNSCC, like most forms of cancer, is dependent on angiogenesis, the growth of blood vessels. We have developed a mime...